Dupilumab patent expired?

Dupilumab (Dupixent) patents have been partly expired / approaching expiry in some jurisdictions, but the situation is not uniform worldwide—there are usually multiple patents (compound, formulation, methods-of-use, second medical use, exclusivities, etc.), plus regulatory exclusivities (like orphan/biologic exclusivity) that can delay true generic/biosimilar launch.

What’s generally true

• Original “compound” patents for dupilumab are widely understood to have expired or be nearing expiry, especially in major markets.
  
• However, other patents and exclusivities can still protect certain indications, dosing regimens, or specific formulations.
  
• Because dupilumab is a biologic, the “generic” equivalent is typically a biosimilar (or sometimes an interchangeably approved product).
  
  

  What this means for biosimilars
  

• Some regions have already had biosimilar competition, and others may have delayed entry due to remaining patent coverage for particular claims/indications.
  
• Whether a biosimilar is available (and when) depends on:
  
  1. the country
     
  2. which indication (asthma, AD, CRSwNP, etc.)
     
  3. which patents remain in force for that country/indication
     
  4. whether biosimilar approval has been granted and is marketed
     
     

     Quick question (so I can answer precisely)
     

     Which country/region are you asking about (US, EU, UK, Canada, India, etc.), and for which indication (e.g., atopic dermatitis, asthma, CRSwNP)?
     
     If you tell me the jurisdiction, I can summarize the likely status of relevant patent estates and remaining exclusivity barriers there.